Pembrolizumab + Axitinib — combined immunotherapy and targeted treatment for kidney cancer

What is pembrolizumab + axitinib in simple words

Pembrolizumab + axitinib — two drugs used together as a first-line treatment for advanced kidney cancer.

They work through completely different mechanisms. Pembrolizumab removes a suppressive signal the tumour uses to hide from immune cells. Axitinib cuts off the blood supply the tumour needs to grow — it targets proteins that drive the formation of new blood vessels inside and around the cancer.

Running them together is not simply about intensifying treatment. Each drug addresses a different aspect of how kidney cancer sustains itself. Clinical data showed that the combination produced better outcomes than using either drug alone or the previous standard approach. That is the rationale for pairing them.

But this is not the right choice for every patient with kidney cancer. Stage, prior treatment, organ function and the specific characteristics of the tumour all shape the decision.

How this combination works

Pembrolizumab blocks a receptor on immune cells that some tumours use to switch those cells off. Once that block is removed, immune cells can start recognising and responding to the cancer.

Axitinib works through an entirely different pathway. It blocks proteins — specifically a family of receptors involved in blood vessel formation. Tumours depend heavily on new blood vessel growth to sustain themselves. Axitinib disrupts that process, restricting the blood supply the cancer relies on.

The two approaches act simultaneously on different vulnerabilities of the tumour. Whether that produces a meaningful response in a specific patient depends on the cancer’s molecular features, stage and the patient’s overall condition.

What conditions this combination is used for

Pembrolizumab and axitinib together are used as a first-line treatment in:

• advanced kidney cancer — clear cell subtype;

• kidney cancer that has spread to other organs;

• patients who have not received prior systemic treatment for this cancer.

Kidney cancer was one of the first cancer types where combining immunotherapy with a drug that targets blood vessel growth showed a meaningful clinical benefit over the previous standard. Trial data demonstrated improvements in both how long patients went without the cancer growing and in overall survival, across different patient risk groups.

The clear cell subtype is important to note. This is the most common form of kidney cancer, and it is the population in which this combination has the strongest evidence. Other subtypes of kidney cancer have different biological profiles and may not respond in the same way.

When this combination may be especially relevant

It tends to come up when:

• kidney cancer has spread and requires first-line systemic treatment;

• the tumour is of the clear cell subtype;

• the patient has not previously received immunotherapy or a targeted drug for this cancer;

• surgery cannot adequately control the disease;

• the patient’s organ function supports tolerating both drugs simultaneously.

The first-line setting is where this combination has its strongest evidence. Using it after other treatments have already been tried is a different situation with different evidence — and different expectations.

Sometimes the decision is straightforward. Sometimes it involves weighing this combination against others that also have strong supporting data in kidney cancer — each with different toxicity profiles and different practical considerations. I discuss the options side by side before recommending one.

What needs to be checked before starting treatment

Before this combination is considered, the oncologist will typically assess:

• confirmed histology — clear cell versus other subtypes;

• disease stage and extent of spread;

• imaging of the kidneys, chest and abdomen;

• prognostic risk score — several clinical factors combine to estimate how the disease is likely to behave;

• blood pressure at baseline — axitinib affects it significantly;

• thyroid function;

• liver function;

• kidney function — the remaining kidney if one has been removed;

• cardiovascular history;

• autoimmune history;

• performance status.

Blood pressure is the one I focus on most carefully before starting axitinib. The drug raises it reliably — sometimes substantially. Patients who already have hypertension need their baseline controlled before the first dose. I ask every patient to have a home blood pressure monitor in place before we start. Readings between visits tell me considerably more than a single measurement at each appointment.

How treatment is carried out

Pembrolizumab is given intravenously every three weeks. Axitinib is taken as a tablet twice daily — every day, not just on infusion days. That daily oral component is something patients need to be clear on before starting.

Monitoring during treatment:

• blood pressure at every visit — and at home between visits;

• thyroid function at set intervals;

• liver function tests;

• kidney function;

• full blood count;

• imaging every eight to twelve weeks to assess response;

• monitoring for immune-related side effects from pembrolizumab;

• monitoring for targeted therapy side effects from axitinib.

Two drugs running simultaneously means two overlapping monitoring requirements. The axitinib side effects — blood pressure, hand-foot skin reactions, fatigue — are different from the immune-related effects of pembrolizumab. Managing them requires distinguishing which drug is causing which symptom. That is not always straightforward, but it matters for how each is managed.

Possible side effects

Side effects can come from both components:

• high blood pressure — from axitinib, often significant;

• hand-foot skin reaction — redness, soreness, thickening on palms and soles;

• diarrhoea;

• fatigue;

• thyroid dysfunction — from either drug;

• nausea and reduced appetite;

• immune-related skin rash or itching;

• liver enzyme elevation;

• lung inflammation;

• mouth sores;

• hoarseness of voice — from axitinib;

• rarely — serious cardiac or neurological involvement.

Hand-foot skin reaction is the side effect patients are often least prepared for. It starts as redness and sensitivity on the palms and soles, and can progress to painful thickening and cracking if not managed. Good foot care, moisturising and avoiding pressure on affected areas help. But the key is reporting it early — dose adjustment of axitinib, when needed, prevents it from becoming debilitating.

When to contact a doctor urgently

Do not wait if any of the following develop:

• a significant rise in blood pressure — especially if accompanied by headache;

• worsening shortness of breath;

• chest pain;

• severe diarrhoea;

• blood in the stool;

• yellowing of the skin or eyes;

• severe hand-foot reaction preventing walking or normal activity;

• confusion or rapidly increasing weakness;

• sudden significant deterioration.

Blood pressure elevation on axitinib can be sudden. If a patient reports a headache alongside a high reading, that needs same-day assessment. Waiting to see if it resolves is not the right approach here.

Why this combination is not right for everyone

What affects whether this is the appropriate approach:

• kidney cancer subtype other than clear cell — different biology, different evidence;

• prior systemic treatment — this combination’s evidence is strongest as a first treatment;

• uncontrolled high blood pressure before starting;

• significant cardiovascular history;

• active severe autoimmune disease;

• prior organ transplant;

• poor performance status or organ function.

Several other combinations also have strong evidence in this setting — each with a different toxicity profile. Some patients do better on a combination that avoids the blood pressure effects of axitinib. Others do better avoiding the intensity of dual checkpoint blockade. The choice between them is a clinical conversation, not a default.

Can the combination be modified

Axitinib is taken at a starting dose that can be adjusted — increased if well tolerated, reduced if side effects become difficult to manage. That flexibility is built into how the drug is used. Pembrolizumab dose does not change, but it can be held temporarily if immune-related toxicity requires it.

Whether to continue both drugs, hold one, or pause the regimen entirely depends on what is happening clinically. These decisions are made individually at each assessment.

What ‘no quick response’ means

Targeted therapy with axitinib often produces earlier visible changes than immunotherapy alone. Some patients see scan improvement after the first cycle. Others take longer. Pembrolizumab builds more gradually.

With both running together, the picture on early scans can be mixed. I look at imaging alongside symptoms, blood markers and how the patient actually feels. One scan at twelve weeks is a data point, not a verdict.

Oncology consultation for pembrolizumab + axitinib in Israel

At Tel Aviv Medical Clinic in Israel, consultations are available on the combination of pembrolizumab and axitinib for advanced kidney cancer. Oncologists at the clinic follow ESMO and NCCN guidelines and have experience selecting between the various combination regimens available in this setting based on patient profile, risk group and individual tolerability considerations.

In Tel Aviv Medical Clinic, you can discuss:

• whether this combination is appropriate for your kidney cancer subtype and stage;

• how this combination compares to other first-line options in this setting;

• blood pressure and cardiovascular assessment before starting axitinib;

• managing hand-foot skin reaction during treatment;

• second opinion on a proposed treatment plan;

• treatment options available in Israel and internationally.

Sometimes the most important question is not whether to treat, but which combination fits this patient’s disease and tolerance profile best.

Frequently Asked Questions — Dr. Stefanskoy

1. Why combine immunotherapy with a targeted drug rather than using one alone?

Because kidney cancer uses multiple mechanisms to sustain itself. Immunotherapy addresses one — the suppression of immune cells. A drug targeting blood vessel formation addresses another — the tumour’s ability to build the supply network it needs to grow. Blocking both simultaneously proved more effective than either approach alone.

This was not obvious at the outset. There were theoretical reasons to think the two might interfere with each other. The clinical data showed they did not — and that the combination produced better results. That is now the basis for using them together as a standard first-line approach.

2. How much does blood pressure change on axitinib?

Significantly in many patients. Axitinib reliably raises blood pressure — it is one of the most consistent effects of this class of drugs. For patients who already have some degree of hypertension, baseline control before starting is important. For those with normal baseline blood pressure, the rise is still worth monitoring closely.

I ask every patient to get a home monitor before the first dose. Daily readings give a much clearer picture than clinic measurements alone. If pressure rises substantially, medication is adjusted. Catching that early makes it manageable and prevents it from becoming a reason to hold or reduce the axitinib.

3. What is the hand-foot skin reaction and how serious is it?

It is a side effect that shows up on the palms of the hands and soles of the feet — redness, sensitivity, sometimes painful thickening and cracking. It is caused by the targeted drug component. It ranges from mild and manageable to severe enough to affect walking or daily function.

The key is reporting it early. Mild cases respond well to moisturising, gentle footwear and avoiding pressure on affected areas. If it worsens, the dose of the targeted drug can be reduced. I tell patients: do not wait until it is painful to mention it. Report any changes at the palms or soles from the first cycle onward.

4. Does the cancer subtype matter?

Yes — significantly. The clear cell subtype is the most common form of kidney cancer and the one in which this combination has the strongest evidence. Other subtypes have different biology and may not respond in the same way.

If a pathology report shows a non-clear cell subtype, the choice of treatment is a different conversation. Some non-clear cell subtypes have their own specific treatment approaches. Others have less established evidence for any systemic regimen. Getting the histology right matters before any treatment discussion begins.

5. How is the prognostic risk score used in kidney cancer?

A set of clinical factors — including haemoglobin level, calcium, certain blood count parameters, time from diagnosis and performance status — combine to place patients into risk groups. This classification helps predict how the disease is likely to behave and informs which treatment combination has the strongest supporting evidence.

Pembrolizumab and axitinib showed benefit across different risk groups in clinical data. But risk category still influences how results are interpreted and what expectations are realistic. I always calculate it and explain what it means for the specific patient.

6. What happens if the combination stops working?

That depends on which drugs have already been used and what the cancer’s current behaviour looks like. Second-line options in kidney cancer include other targeted agents from the same drug class, combinations involving a different immune checkpoint drug, and drugs with entirely different mechanisms.

Clinical trials are also worth discussing early — not as a last resort. Kidney cancer has seen rapid development of new treatment approaches in recent years, and trial access can be genuinely meaningful in this disease.

7. Are there alternatives if this combination is too toxic?

Yes — several. Other first-line combinations for advanced kidney cancer exist, each with a different balance of efficacy and side effects. Some avoid the blood pressure and hand-foot effects of axitinib by using a different targeted component. Others use two immune checkpoint drugs together, which has a different toxicity profile entirely.

The choice between these options is not based on which is most intensive. It is based on which fits the individual patient’s biology, cardiovascular profile, tolerance and preferences. I discuss the alternatives before recommending one approach.

Important information

Pembrolizumab combined with axitinib is considered only after a full assessment of diagnosis, histological subtype, disease stage, cardiovascular status, organ function and overall patient condition.

Do not start, stop or change treatment without consulting your treating physician.

For a consultation in Israel:

📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108